Oral Proteins and Peptides Market by Drug Type (Linaclotide, Plecanatide, Calcitonin, Insulin, and Octreotide) and by Application (Gastric & Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders, and Others)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 – 2029

                                          
Abstract
                    
The report covers forecast and analysis for the oral proteins and peptides market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the oral proteins and peptides market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oral proteins and peptides market on a global level.

In order to give the users of this report a comprehensive view of the oral proteins and peptides market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a customer and region segments which are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market on the global and regional basis. 

The study provides a decisive view of the oral proteins and peptides market by segmenting the market based on customer and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.
 
By drug type, the global oral proteins and peptides market is divided into insulin, linaclotide, calcitonin, plecanatide, and octreotide. Among these products, insulin is expected to account for the largest share of the market. Linaclotide was the fastest growing segment in 2017 and is expected to grab the largest share of total revenue in the coming years.

By application segment, the global oral proteins and peptides market is divided into diabetes, bone diseases, hormonal disorders, gastric & digestive disorders, and others. Diabetes was the leading application segment accounting largest revenue share in 2016. 

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further divided into major countries including the U.S., Germany, France, the UK, China, Japan, India, and Brazil. This segmentation includes demand for oral proteins and peptides based on individual segment and applications in all the regions and countries.

Some of the key players in oral proteins and peptides market include Allergan Plc, Chiasma, Inc., Synthetic Biologics, Generex Biotechnology Corp., Proxima Concepts Limited (Diabetology Ltd.), Novo Nordisk A/S, and Tarsa Therapeutics Inc., Synergy Pharmaceuticals Inc., Sanofi S.A., Biocon Limited, F. Hoffmann-La Roche AG, AstraZeneca Plc, Inc., Hovione Limited, Novartis International AG, among others.

This report segments the global oral proteins and peptides market as follows:

Global Oral Proteins and Peptides Market: Drug Type Segment Analysis

	Integrated Drug
	Linaclotide
	Plecanatide
	Calcitonin
	Insulin 
	Octreotide 

Global Oral Proteins and Peptides Market: Application Segment Analysis

	Gastric & Digestive Disorders
	Bone Diseases
	Diabetes 
	Hormonal Disorders
	Others

Global Oral Proteins and Peptides Market: Regional Segment Analysis

	North America
	
		The U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	The Middle East and Africa